Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ultragenyx Pharmaceutical ( (RARE) ) has shared an update.
On February 3, 2026, Ultragenyx Pharmaceutical reported new long-term clinical data for UX111 (rebisufligene etisparvovec), its investigational AAV9 gene therapy for Sanfilippo syndrome type A, showing substantial and durable reductions in cerebrospinal fluid heparan sulfate and clinically meaningful improvements in cognition, communication, and motor function versus natural history in younger children, as well as retention of key functional abilities in later-stage patients, with a favorable safety profile over a median 4.8-year follow-up as of a September 2025 data cutoff. These results, which will be presented at WORLDSymposium 2026, have been incorporated into a resubmitted Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of UX111, positioning the program for a potential regulatory decision in the third quarter of 2026 and underscoring Ultragenyx’s bid to strengthen its presence in the rare-disease gene therapy market and deliver a first-of-its-kind treatment option for a fatal pediatric disorder.
The most recent analyst rating on (RARE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.
Spark’s Take on RARE Stock
According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative cash flow, and leverage), reinforced by a technically weak longer-term price trend. This is partially offset by a constructive earnings-call outlook, including raised confidence in revenue growth and strengthened near-term financing via nondilutive capital, while valuation remains difficult to assess due to negative earnings and no dividend.
To see Spark’s full report on RARE stock, click here.
More about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases, with a portfolio that includes investigational gene therapies targeting severe pediatric neurodegenerative conditions such as Sanfilippo syndrome type A (MPS IIIA).
Average Trading Volume: 2,471,543
Technical Sentiment Signal: Sell
Current Market Cap: $2.32B
See more insights into RARE stock on TipRanks’ Stock Analysis page.